Wilson M, McDade C, Beby-Heijtel AT, Waterval-Overbeek A, Sundaram V, Perdrizet J. Assessing public health impact of five pediatric pneumococcal conjugate vaccination strategies in the Netherlands. Infect Dis Ther. 2023 Jul;12(7):1809-21. doi: 10.1007/s40121-023-00828-8
Huang L, McDade C, Perdrizet J, Wilson M, Warren S, Nzenze S, Sewdas R. Cost-effectiveness analysis of the South African infant national immunization program for the prevention of pneumococcal disease. Infect Dis Ther. 2023 Mar;12(3):933-50. doi: 10.1007/s40121-023-00767-4
Lucas A, Wilson M, Sings HL, Pugh S, Jones D, Farkouh R, Gessner B, Wasserman M. Estimating the vaccine effectiveness against serotype 3 for the 13-valent pneumococcal conjugate vaccine: a dynamic modeling approach. International journal of infectious diseases and therapy. 2019 Dec;4(4):56-66. doi: 10.11648/j.ijidt.20190404.12
Wilson M, Moffatt M, Mignon A, McDade C, Wasserman M. Potential public health impact model assessing the switch back to use of the 13-valent infant pneumococcal conjugate vaccine in Belgium on children under 18 years. Poster presented at the World Society for Pediatric Infectious Diseases (WSPID) Conference; November 2019. Manila, Philippines.
Wasserman M, Palacios MG, Grajales AG, Berenice Baez-Revueltas F, Wilson M, McDade C, Farkouh R. Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico. Hum Vaccin Immunother. 2019;15(3):560-9. doi: 10.1080/21645515.2018.1516491
Wilson M, Wasserman M, Jadavi T, Postma M, Breton MC, Peloquin F, Earnshaw S, McDade C, Sings H, Farkouh R. Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada. Infect Dis Ther. 2018 Sep;7(3):353-71. doi: 10.1007/s40121-018-0206-1
Wilson MR, Azzabi Zouraq I, Chevrou-Severac H, Selby R, Kerrigan MC. Cost-effectiveness of vedolizumab compared with conventional therapy for ulcerative colitis patients in the UK. Clinicoecon Outcomes Res. 2017 Oct 16;9:641-52. doi: 10.2147/CEOR.S135609
Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273